H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix Inc. (NASDAQ:OCUL) and raised the price target to $21 from $19. H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission The research firm remains confident about the company’s outlook following the submission of a new drug application for AXPAXLI, its 450 µg ax ...